AstraZeneca’s and mRNA vaccines provide equivalent protection against COVID-19 hospitalisation and deaths

Bangkok – AstraZeneca’s COVID-19 vaccine and mRNA COVID-19 vaccines, the world’s most-used1 vaccines, provide equivalent protection against hospitalisation and death from COVID-19 following two doses, a new expert review of data from 79 real-world studies reveals.2

The newly reviewed data makes it clear that both AstraZeneca’s vaccine, which is known as a viral vector vaccine, and ‘mRNA’ COVID-19 vaccines, offer equivalent protection against hospitalisation (91.3-92.5%) and death (91.4-93.3%), regardless of age, with no statistical difference.2 While data available at the time of review relates to Delta and earlier variants, emerging data indicates similar findings on serious COVID-19 outcomes resulting from Omicron.3

Professor Guy Thwaites, Director of the Oxford Clinical Research Unit in Vietnam, said: “COVID-19 vaccines have been critical to saving lives and helping Southeast Asia countries return to some normalcy over the past year. Our expert review shows that the AstraZeneca and available mRNA vaccines provide similar, high-level protection against life-threatening COVID-19. This is important information for the region’s policy makers as they consider the optimal deployment of COVID-19 vaccines in their populations over the next 12 months”

Dr Sunate Chuenkitmongkol, Deputy Director, National Vaccine Institute of Thailand, said: “We have to look at all of the evidence, not only antibody levels but also vaccine effectiveness in real-world settings, to prove that a vaccine works and can effectively protect people from serious outcomes including hospitalisations and deaths. We have reviewed 79 relevant real-world publications and proved that the most widely used viral vector vaccine and the available mRNA vaccines demonstrate high and equivalent protection against severe outcomes of COVID-19.”

The data, reviewed by infectious disease experts from across Asia, comes from VIEW-hub, an interactive platform for visualizing global data on vaccine use and impact developed by Johns Hopkins Bloomberg School of Public Health and the International Vaccine Access Center. The platform is updated on a weekly basis to include global real-world studies on vaccine effectiveness. The 79 real-world studies reviewed included comparative effectiveness data for AstraZeneca’s vaccine and mRNA vaccines, specifically BNT162b2 and mRNA-1273. The VIEW-hub platform is not currently designed to capture the safety outcomes of these studies, preventing similar safety comparisons.

AstraZeneca’s vaccine is a ‘viral vector’ vaccine, which means a version of a virus that cannot cause disease is used as part of the vaccine,,so if the body is exposed to the real virus later it is able to fight it.  This vaccine technology has been used by scientists over the past 40 years to fight other infectious diseases such as the flu, Zika, and HIV.4

AstraZeneca and its global partners have released over 2.9 billion vaccine doses to more than 180 countries, and approximately two-thirds of these doses have been delivered to low- and lower-middle income countries. The vaccine is estimated to have helped prevent 50 million COVID-19 cases, five million hospitalisations, and to have saved more than one million lives.

AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

AstraZeneca is based in six different locations across the UK, with its global headquarters in Cambridge. In the UK, almost 8,000 employees work in research and development, manufacturing, supply, sales and marketing. We supply 34 different medicines to the NHS, which treat more than one million UK patients every year. For more information, Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca

References

1.      Coronavirus (COVID-19) Vaccinations. Our World in Data. Available at https://ourworldindata.org/covid-vaccinations. Accessed April 2022.

2.      Chuenkitmongkol S, Solante R, Burhan E et al. A Southeast Asia Expert Review of Global Real-World Vaccine Effectiveness Against SARS-CoV-2, 25 April 2022. [Preprint] Available at Research Square. https://doi.org/10.21203/rs.3.rs-1575499/v1

3.      UK Health Security Agency: Research and analysis. COVID-19 vaccine weekly surveillance reports (weeks 39 to 12, 2021 to 2022). Data on the real-world effectiveness and impact of the COVID-19 vaccines. Available at https://www.gov.uk/government/publications/covid-19-vaccine-weekly-surveillance-reports?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=9ed25929-064b-4b0e-8cbb-cae7639135d7&utm_content=daily. Accessed April 2022.

4.      Sai V Vemula & Suresh K Mittal (2010). Production of adenovirus vectors and their use as a delivery system for influenza vaccines, Expert Opinion on Biological Therapy, 10:10, 1469-1487, DOI: 10.1517/14712598.2010.519332.